

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 21797

Title: Viro-Immunotherapy: A new strategy for treatment of pancreatic cancer

Reviewer's code: 00068120

Reviewer's country: China

Science editor: Ze-Mao Gong

Date sent for review: 2015-07-30 17:09

Date reviewed: 2015-08-16 09:24

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input checked="" type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

no

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 21797

Title: Viro-Immunotherapy: A new strategy for treatment of pancreatic cancer

Reviewer's code: 00001832

Reviewer's country: Germany

Science editor: Ze-Mao Gong

Date sent for review: 2015-07-30 17:09

Date reviewed: 2015-09-16 13:02

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input checked="" type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

The manuscript by Andrea Marie Ibrahim and Yaohe Wang reviews viro-immunotherapy as a new strategy for treatment of pancreatic cancer. This is a nicely written review about an important and emerging topic. The latest data are summarized and the relevant literature is cited. I have only a few minor comments: The authors state that "CDKN2A, TP53, BRCA2 and SMAD4 which occur in higher grade lesions are also commonly found". However, BRCA2 mutations are not so common as the other three mentioned gene mutations/alterations. The sentence "Hanahan and Weinberg ... in their infamous review", should read "famous" review.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 21797

Title: Viro-Immunotherapy: A new strategy for treatment of pancreatic cancer

Reviewer's code: 00042283

Reviewer's country: Italy

Science editor: Ze-Mao Gong

Date sent for review: 2015-07-30 17:09

Date reviewed: 2015-09-27 23:43

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input checked="" type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

The review is well written but it deals with the all fields of immunotherapy. Therefore either you eliminate all chapters on anti CTL4 and anti PD1/PDL-1 either you change the title deleting viro from immunotherapy. Minor comments: 1) The introduction with a discussion of the limits of the traditional therapeutic approach in pancreatic cancer is too long (4 pages, 1 figure, 35 ref). Please shorten it 2) In anti CTL\$ you should mention the phase 1 study with tremelimumab in pancreatic cancer (Annals of Oncology 25: 1750-1755, 2014)

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 21797

Title: Viro-Immunotherapy: A new strategy for treatment of pancreatic cancer

Reviewer's code: 02544990

Reviewer's country: Japan

Science editor: Ze-Mao Gong

Date sent for review: 2015-07-30 17:09

Date reviewed: 2015-09-28 17:12

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

This manuscript reviews about the current treatment strategy for pancreatic cancer mainly focusing on the combination therapy of oncolytic virotherapy and immune checkpoint blockade agents. The manuscript is well written full of cutting edge information for the treatment strategy of pancreatic cancer. However, there are several comments which further strengthen the manuscript. Firstly, I wonder the association between TOVs and enhanced immune responses induced by anti-immune checkpoint agents is the two edged sword. The immune responses would be increased by these agents, while at the same time the TOVs by themselves would also be affected or cancelled by these agents through blocking infection into the tumor cells or possible direct targets by the enhanced immune cells or antibodies overcoming immune tolerance. The authors should comments to these problems utilizing these new agents. Secondly, the authors describes hurdles for the oncolytic virotherapy only from the point of view of immune escaping or immunological tolerance. Other possible mechanisms which hampers oncolytic virotherapy at the present situation should also be commented in this review manuscript.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 21797

Title: Viro-Immunotherapy: A new strategy for treatment of pancreatic cancer

Reviewer's code: 00068107

Reviewer's country: China

Science editor: Ze-Mao Gong

Date sent for review: 2015-07-30 17:09

Date reviewed: 2015-09-29 19:50

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

No